APELLIS PHARMACEUTICALS INC - NASDAQ: $APLS Knocking On DoorAfter breaking-out in early Spring (March), APELLIS PHARMACEUTICALS INC - NASDAQ:APLS has been building-out its right side in a prolonged base and presently finds itself nearing a potential move that may just catapult the stock into higher ground as evidenced in the Daily chart above.
While further work is required, APLS presently trades above all of its important moving averages 20/50/200 DMA's, which depicts a healthy technical posture.
Additionally, when one extends the time-frame out to the Weekly chart, we can also observe that APLS is presently knocking on the door to a potential move out of its long-drawn base.
Thus, both investors/traders may want to pay close attention to the action in the days/weeks ahead for further clues/evidence that APLS may just be on the verge of breaking free from its base.
Should APLS be capable of going topside of the $22.25 figure at any time in the days ahead, such development, should it occur, would like trigger its next meaningful advance into higher ground with and initial $24-$26 objective and perhaps higher.
PHARMA
AMARIN CORP - NASDAQ: $AMRN Setting-UpAfter breaking to higher ground in 1Q19 and subsequently drifting back down to its original break-out level in the upper teen's, the shares of AMARIN CORP NASDAQ: AMRN are once again starting to show signs of potentially setting-up for another attempt at loftier levels as evidenced in the Daily chart above.
While AMRN presently finds itself in drift mode working on its right-side, the stock continues to display favorable technical characteristics trading above all of its important moving averages (20/50/200 DMA's).
Although further work is required, it appears that we may just witness a repeat of 1Q whereby buyers once again start to take control of the stock and should such scenario materialize, we suspect that it may have eyes for the $22 - $24 zone once again in the short-term.
Thus, both investors/traders may want to continue to monitor the action closely in the days/weeks ahead for signs/clues that a move for greener pastures is underway.
BIOMARIN - GOOD BUY OPPORTUNITYToday we gonna look at the pharmaceutical company, as a potential new giant trend on the stock market. NASDAQ:BMRN laying on the strong support line near $87.87 and can move up suddenly. My recommendation:
1. Buy now around 87.87
2. Take profit: 109.45
3. SL: 78.68
Risk/Reward - 2.39, potential profit - 24,6%
Pieris Pharmaceuticals Inc. NASDAQ: PIRS Shaping-Up
Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. The company's clinical pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, inhaled Anticalin proteins to treat respiratory diseases, such as uncontrolled asthma, and a half-life-optimized Anticalin protein to treat anemia.
TECHNICAL
After breaking-out on large meaningful volume two weeks ago, shares of Pieris Pharmaceuticals Inc. - PIRS now finds itself digesting/consolidating the recent thrust into higher ground on lower volume and in a very constructive manner.
When observing the Daily chart above, we can see that PIRS is coming out of a rounding bottom and has recaptured its 200 DMA on the recent move. In addition, we can also see that PIRS now finds itself trading above all of its important moving averages (20/50/200 DMA's), which depicts a favorable technical posture.
Both investors/traders may want to continue to monitor the action closely in the days/weeks ahead as we would not be surprised if a move into the $5- $6 zone were to occur in the not too distant future.
ZYNE going up after correction (BULL)Zynerba crashed into resistance at at $16.50 on May 17th 2019, and went into correction territory.
The engulfing candlestick today May 29th, 2019 is a very bullish sign ZYNE could go up to at least the $16.50 line.
Technicals are not great, however I expect them to start confirming the bullish trend soon.
Recommended trade:
Long: $13.15 (20SMA)
Sell-target: $16.40
Stop-loss: $11.5
2.59p / 5.5p targets - Trend reversal - RSI strongBought at 1.86p & 1.74p today.
Company turning around with new CEO & new plans moving ahead.
Amazing tech with a huge amount of potential.
Cash in bank with last placing a month ago at 1.6p so plenty of time to grow.
Ending Diagonal setting up great opportunity on ZIOPPerfect setup forming for a good short opp from $5.00 - $3.25
retrace / breather before next leg - 2.7p support 4.39p resistanChart is in a range at moment with over 4.39p will be a breakout.
I would look for 2.7p for a potential entry / scale in if keen on the company
look for a retouch of the t-line.
at times it is best to start scaling in ahead of support in case u miss it
Selling the cannabis bubble Here we can see the beginning of a large sequence to the downside in many cannabis stocks. I am going short across the board here as the sector looks very soft and recommending all to write upside volatility or simply short the common stock for infinity.
From a technical perspective we are struggling at heavy resistance and beginning a new sequence to the downside.
Sit tight, the global downturn is coming.
72p - 74.4p possible entry / 96.8p - 121p resistanceReally like this chart & can see a good rise after MM's pull price down to support at 74.4p - also 200ma weekly at 72p
Best to scale in near the support level but watch out if RSI support level is not respected or 200ma as well, be ready to move out if so.
Bearish possibly 1.18p before next leg to 2.59p - 5.49pLook for retrace of RSI to support or 1.18p (whatever comes first) before re-entry or top-up
it failed to brake 2.59p resistance so therefore it will need a breather if no news
5.49p next resistance if 2.59p is broken.
If 1.18p is lost run for the hills!
Innovate Biopharmaceuticals 3.55 target on good reportinglot of lines and PTs can elevate fast if this breaks out on volume inflation in April
Notice the 1M candle is Red 9 for March. Ideal play here is an entry under $2.00 (on support retest)
if we change cycle from accumulation to Bull Cycle, look for late 2019 take profit area (Sept-Dec)
Long GBIO33, Short HYPE3Long GBIO33 and Short HYPE3 on breakout from multiple timeframes negative trend line and GBIO33's strong bounce off lows. Fundamentally, HYPE3 well priced while GBIO33 is an undervalued growth case.
FSD Pharma (HUGE) - accumulation before next move upFSD Pharma looks like it is in accumulation, before a move upwards that could reach as far as the local resistance 'first trouble area' before retracing back down - there would need to be significant upswing in buying volume to go further than that.
Indicators -
Bollinger Bands looks awfully similar to how they did in July 2018 shortly before accumulation and bull run.
RSI shows price currently sitting at support level.
10 Day MA is pretty neutral, no major bullish momentum but not falling under either.
This would be a good play if buying in the green box and selling somewhere in the region of the first trouble area.
IBB Correction IncomingPsychology of a Market Cycle Cheat Sheet: goo.gl
IBB's chart is identical to the chart on the market psychology cheat sheet linked above.
IBB 5-wave cycle is over + Truncated 5th
Algorithms exit the market after extended 3rd waves, leaving the 5th with no volume nor liquidity, just as it's done for IBB .
Current Market Condition: Complacent. Just "cooling off for the next rally".
50%-60% Downside.